InMed Leadership Monday, November 16, 2026 -0.60 Negative

InMed Reports H1 2026 Fourth Quarter Financial Results

Mentari Therapeutics (formerly InMed) reported unaudited financials showing total assets of $52.44 million as of September 2026, with an associated note payable of nearly $50 million to a related party. The company formerly known as InMed Pharmaceuticals is being evaluated for potential sale, given InMed's decision to terminate its Merger Agreement. The shift in operations and financial reporting marks a significant rebranding and strategic pivot change.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed